PGM5 and metastatic prostate carcinoma: In the present study, our results demonstrate that PGM5 expression is decreased in primary and metastatic prostate cancer by bioinformatic analyses and immunohistochemical assessment, which indicate a novel role for PGM5 as an important diagnostic and prognostic marker in prostate cancer.